Otsuka Pharmaceutical and Click Therapeutics have announced the launch of a new, fully remote clinical trial being conducted on Verily's Project Baseline platform.
Called the Mirai study, it will be measuring a digital therapeutics intervention's effectiveness in reducing symptoms of depression among adults who have a major depressive disorder (MDD) diagnosis and are on antidepressant monotherapy...
Digital therapeutics have been plodding on a steady path toward acceptance within healthcare, but the modality reached new heights during a year of unprecedented adoption for digital health technologies. More and more software-based treatments are picking up regulatory approvals – including three De Novo clearances in 2020 alone – while the ongoing COVID-19 pandemic has exposed more consumers,...
Put your X-ray where your mouth is. After fielding accusations of fraud that temporarily damaged the value of its stock, digital X-ray-imaging company Nanox gave a highly publicized live (but virtual) demonstration of its imaging technology at the Radiology Society of North America's annual meeting.
The demo – a recording of which Nanox said will be available to the public later today from the...
The increased adoption of virtual care technologies during the COVID-19 public health emergency is fairly well documented by this point, but a widespread embrace of health technologies is providing a similar upswell on individual niches within the digital health landscape.
One such group of beneficiaries are the companies working to develop, validate and distribute digital therapeutics. Speaking...
International pharma Boehringer Ingelheim and prescription digital therapeutics company Click Therapeutics have inked a $500 million-plus deal to jointly develop and commercialize a digital treatment for patients with schizophrenia.
The treatment, referred to as CT-155, will be a mobile app built on Click's proprietary tech platform, the companies said.
Employing cognitive and neurobehavioral...
There’s no denying that digital therapeutics look and feel different than traditional medications. Instead of popping open a medication bottle, users are logging into an app to access treatment. But the differences don’t stop at the look. While the risk of toxicity is an ever-looming question in the pharma space, the same isn’t true for digital solutions.
Stakeholders at the digital therapeutics...
This morning Otsuka America, a subsidiary of the Japanese pharma company, announced that it is teaming up with Click Therapeutics, maker of software as a prescription medical treatment, to create a new digital therapeutic to treat major depressive disorder (MDD).
The goal of the partnership is to develop a software app that will employ cognitive therapy principles and can be used either with or...
Behavioral health technology provider AbleTo has announced Trip Hofer as its new CEO. Hofer most recently held the title of president of accordant health services as CVS Specialty, and prior to that held senior positions at OptumHealth and Health Dialog.
“I am thrilled to join an organization whose singular purpose is to tackle one of the biggest challenges facing our country: the behavioral...
This morning, prescription digital therapeutic developer Click Therapeutics closed a $17 million funding round led by Sanofi Ventures, a subsidiary of pharma giant Sanofi.
“We’ve evaluated many companies in this space, and we believe Click Therapeutics’ mobile patient engagement platform positions the company to be a leader in the field of prescription digital therapeutics,” Bernard Davitian,...
The past month has seen a succession of publications offering support for Click Therapeutics’ digital offering for patients with major depressive disorder (MDD).
The studies, published in npj Digital Medicine, the Journal of Affective Disorders, and presented at the Society of Biological Psychiatry Annual Scientific Convention in New York, showed the therapeutic to reduce symptoms, pair well with...
